Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.

Trailblazing BGE CEO; Honored for Transformational Impact in Utility Sector Jul. 18, 2025 / PRZen / BALTIMORE — The 30th ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...

Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is ...

TORONTO, ONTARIO / ACCESS Newswire / July 18, 2025 / Walkrite Foot Clinic, a trusted name in expert podiatric care for over ...

As more people move away from busy commercial gyms and begin setting up dedicated areas at home, there’s been a noticeable shift in the type of training equipment that draws attention. The focus has ...

Sarepta Therapeutics, Inc. ( NASDAQ: SRPT) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Douglas S. Ingram - President, CEO & Director Ian Estepan - ...

Sarepta Therapeutics saw its shares plunge more than 35% Friday after a third patient death tied to its gene therapy programs ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss, but new therapies are reshaping its treatment.

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Borrowing from the anti-inflammatory properties of olive oil, Penn Engineers used a century-old chemical reaction to redesign ...